Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer


Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power into a new suite of untargeted and targeted LC/MS/MS workflows. The system combines the power of Travelling Wave (T-Wave) Ion Mobility Separations with new data acquisition and informatics technologies, and collision cross section (CCS) measurements.

The mass spectrometer is the first MS system to elevate CCS alongside retention time and mass to charge ratio (m/z) as a robust, reliable identification parameter in library-based screening, according to a Waters press statement. The collision cross section of a molecule is an important distinguishing feature that is directly related to its chemical structure and three-dimensional conformation in the gas-phase. Like molecular mass, this additional orthogonal property of a molecule (through the use of high-efficiency T-wave ion mobility technology) gives scientists increased coverage and clarity for profiling mixtures or gaining additional measurements with which they can investigate chemical structures or better confirm a molecule's identity.

The system offers maximized time-of-flight (Tof) duty cycle and effective sensitivity, of up to 10x in MS/MS mode, for targeted discovery and quantitation. Improved LC/MS/MS efficiency includes a 40% improvement in the numbers of proteins identified from an E. coli sample and the identification of more than 2,000 proteins from a HeLa sample. A 2.5KHz solid-state laser combines with new software for improved spatial resolution (down to 15 microns) for cleaner mass spectral data and greater image throughput when performing experiments with MALDI imaging and T-wave ion mobility.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here